责任编辑：小浪快报 中欧价值精选混合A（021181）成立日期2024年5月21日，最新规模4.41亿。今年以来收益8.55%，同类 排名2749/8872；近一年收益37.02%，同类排名3496/8126；成立以来收益52.94%。 中欧价值精选混合A（021181）基金经理为张学明。 截至发稿，张学明累计任职时间1年283天，现任基金资产总规模58.6亿元，任职期间最佳基金回报 88.61%， 任职期间最差基金回报1.73%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本 文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 1月30日，艾比森涨5.74%，截至发稿，报19.88元/股，成交2.04亿元，换手率4.55%，总市值73.38亿 元。 资料显示，深圳市艾比森光电股份有限公司位于广东省深圳市龙岗区坂田街道雪岗路2018号天安云谷产 业园一期3栋A座18,19,20层，成立日期2001年8月23日，上市日期2014年8月1日，公司主营业务涉及 LED应用产品的研发、生产 ...

证券日报网讯1月27日，艾比森（300389）在互动平台回答投资者提问时表示，公司LED小间距产品广 泛应用于智能工业场景，如智能生产调度中心、智能生产制造BI数据看板等，匹配智能生产数据，提升 智能生产的调度指挥效率，赋能智能化高端生产制造。 ...

（上接1版） 同期，新农股份、大洋生物等多家化工企业也呈现出持续向好的经营态势。 作为全球领先的LED显示应用与服务提供商，艾比森预计2025年度归属于上市公司股东的净利润为2.4 亿元至2.9亿元，同比增长105.32%至148.09%。公司强调，经过多年持续深耕与科学布局，进一步深化 本地化运营，构建起高效协同的全球渠道网络，打造出差异化的品牌优势，显著增强了在国际市场的竞 争力。目前业务已覆盖超140个国家，全年实现海外营业收入约31.93亿元，同比增长约8.94%，保持良 好增长态势。 对于楚天科技来说，公司预计2025年归母净利润达2.35亿元至3亿元，一举扭亏为盈。其核心驱动力正 是国际市场的强势突破——公司在东南亚、中东非、美洲地区等取得突破性进展，海外业务进入快速增 长通道，国际业务占比显著提升，带动利润大幅增长。 有色金属板块同样受益于价格高位运行和产能释放，紫金矿业、洛阳钼业、腾远钴业等上市公司业绩均 大幅增长。以紫金矿业为例，公司预计2025年实现归属于上市公司股东的净利润510亿元至520亿元，同 比增长59%至62%。公司业绩增长动力源于主要矿产品产量同比增加，以及矿产金、矿产铜、矿 ...

证券日报网讯 1月16日，艾比森在互动平台回答投资者提问时表示，2025年度公司预计实现营业收入约 为41.56亿元，同比2024年上升约13.46%。其中：海外市场经过多年的持续深耕与科学布局，进一步深 化本地化运营，构建起高效协同的全球渠道网络，打造出差异化的品牌优势，显著增强了在国际市场的 竞争力。海外市场预计实现营业收入约31.93亿元，同比增长约8.94%，继续保持良好增长态势。国内市 场在LED显示整体需求疲软的背景下，通过聚焦优质客户、优化产品结构、调整渠道策略等关键举措， 预计实现营业收入约9.63亿元，同比增长约31.56%，成功实现逆势增长。更多详情请参阅已披露的业绩 预告。 （文章来源：证券日报） ...

声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 有投资者在互动平台向艾比森提问："看公司业绩预告增长还不错，2025年营收增长的主要动能来自哪 里？" 作者：公告君 针对上述提问，艾比森回应称："投资者您好，2025年度公司预计实现营业收入约为41.56亿元，同比 2024年上升约13.46%。其中：海外市场经过多年的持续深耕与科学布局，进一步深化本地化运营，构 建起高效协同的全球渠道网络，打造出差异化的品牌优势，显著增强了在国际市场的竞争力。海外市场 预计实现营业收入约31.93亿元，同比增长约8.94%，继续保持良好增长态势。国内市场在LED显示整体 需求疲软的背景下，通过聚焦优质客户、优化产品结构、调整渠道策略等关键举措，预计实现营业收入 约9.63亿元，同比增长约31.56%，成功实现逆势增长。更多详情请参阅已披露的业绩预告，感谢您的关 注！" 本文源自：市场资讯 ...

Core Insights - A total of 43 companies listed on the ChiNext board have released their performance forecasts for 2025, with 22 companies expecting profit increases, representing 51.16% of the total [1] - The overall proportion of companies forecasting positive performance (including profit increases and profit warnings) stands at 55.81% [1] Performance Forecast Summary - Among the companies forecasting profit increases, 9 are expected to see net profit growth exceeding 100%, while 6 companies anticipate growth between 50% and 100% [1] - The company with the highest expected net profit growth is Huisheng Biological, with a median increase of 1355.24% for 2025 [1] - Other notable companies include Zhongtai Co., expecting a median net profit increase of 677.22%, and Chenguang Biological, with a forecasted increase of 301.38% [1] Companies with Significant Profit Increases - The following companies are highlighted for their substantial expected profit increases: - Huisheng Biological (Code: 300871) - 1355.24% increase, latest closing price: 25.52, year-to-date change: 23.11%, industry: Agriculture, Forestry, Animal Husbandry, and Fishery [1] - Zhongtai Co. (Code: 300435) - 677.22% increase, latest closing price: 29.14, year-to-date change: 31.14%, industry: Public Utilities [1] - Chenguang Biological (Code: 300138) - 301.38% increase, latest closing price: 13.78, year-to-date change: 11.04%, industry: Agriculture, Forestry, Animal Husbandry, and Fishery [1] - Lakala (Code: 300773) - 222.00% increase, latest closing price: 32.08, year-to-date change: 12.64%, industry: Non-banking Financial [1] - Other companies with notable increases include Guokai Technology, Chuanjin Nuo, and Jinli Yong, with expected increases ranging from 144.00% to 158.44% [1]

Core Viewpoint - The controlling shareholder and chairman of Absen (300389), Ding Yanhui, has decided to terminate his share reduction plan, which initially aimed to reduce his holdings by up to 11.073 million shares (3% of the total share capital) due to confidence in the company's stable development [1]. Summary by Relevant Sections - **Share Reduction Plan**: Ding Yanhui originally planned to reduce his stake through centralized bidding and block trading, with a maximum reduction of 11.073 million shares [1]. - **Current Status**: As of the announcement date, Ding Yanhui has only reduced his holdings by 400 shares [1]. - **Decision to Terminate**: Ding Yanhui has decided to terminate the remaining share reduction plan and will not reduce any further shares within the planned timeframe [1].

本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 深圳市艾比森光电股份有限公司（以下简称"艾比森"或"公司"）于 2025 年 10 月 24 日在巨潮资讯网披露了《关于控股股东、实际控制人减持股份的预披 露公告》（公告编号：2025-059）。公司控股股东、实际控制人、董事长丁彦辉 先生拟通过集中竞价、大宗交易的方式减持其持有的公司股份不超过 11,073,009 股（含本数），即不超过预披露公告披露之日公司股份总数的 3%。 公司于近日收到丁彦辉先生出具的《关于股份减持计划提前结束的告知函》， 截至目前，丁彦辉先生已减持股份 400 股，本次减持计划提前结束，剩余未减持 股份在本次减持计划期限内不再减持。现将具体情况公告如下： 一、股东减持基本情况 证券代码：300389 证券简称：艾比森 公告编码：2026-003 深圳市艾比森光电股份有限公司 关于控股股东、实际控制人股份减持计划提前终止的公告 公司控股股东、实际控制人、董事长丁彦辉先生保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 | 股东 | 股份性质 | | 本次减持前持有股份 | 持有股份 ...

证券日报网讯1月13日，艾比森（300389）在互动平台回答投资者提问时表示，公司的全资子公司艾比 森投资公司对睿电绿能等进行投资并持有相应的股权，相关事项已按规定履行披露义务，睿电绿能主要 开展新能源储能业务，致力于为客户提供安全的、智能的、可持续的绿色储能产品和服务，业务涵盖家 庭储能和工商业储能领域，依托母公司全球市场布局优势，储能产品销售及服务网络先后触达欧洲、亚 太及国内市场，已在国内外成功交付多个商用项目。 ...

Core Insights - Approximately 130 A-share companies have disclosed their performance forecasts for 2025, with around 70 companies expecting positive results, including profit increases and turnaround from losses [2][4]. Company Performance Highlights - **Zhongke Lanyun**: Expected net profit of 1.4 billion to 1.43 billion yuan, a year-on-year increase of 366.51% to 376.51%, driven by strategic investments in high-growth areas like GPU and advanced packaging [4][5]. - **Chuanhua Zhili**: Forecasted net profit of 540 million to 700 million yuan, with a growth rate of 256.07% to 361.57%, supported by optimized marketing strategies and asset structure in logistics and chemical businesses [5]. - **Bai'ao Saitou**: Anticipated net profit of 135 million yuan, reflecting a 303.57% increase, attributed to favorable market conditions [4]. - **Kangchen Pharmaceutical**: Expected net profit of 145 million to 175 million yuan, with a growth of 243% to 315%, due to the absence of goodwill impairment losses in the reporting period [5]. - **Guangku Technology**: Projected net profit of 169 million to 182 million yuan, a growth of 152% to 172%, driven by product innovation and cost control [7]. - **Lixun Precision**: Forecasted net profit of 16.518 billion to 17.186 billion yuan, with a growth of 23.59% to 28.59%, supported by innovations in manufacturing and AI integration [6]. - **Daotong Technology**: Expected net profit of 900 million to 930 million yuan, with a growth of 40.42% to 45.10%, driven by AI-driven services [6]. - **Aibisen**: Anticipated net profit of 240 million to 290 million yuan, reflecting a growth of 105.32% to 148.09%, due to increased R&D investment [7]. - **Chaohongji**: Expected net profit of 436 million to 533 million yuan, with a growth of 125% to 175%, supported by a focus on brand optimization and digital transformation [9]. - **WuXi AppTec**: Forecasted net profit of 19.151 billion yuan, with a growth of approximately 102.65%, including gains from divesting joint ventures [9]. - **Hui Sheng Biological**: Expected net profit of 23.5 million to 27.1 million yuan, indicating a turnaround, driven by market expansion and improved production efficiency [9]. Industry Performance Insights - The electronics, semiconductor, pharmaceutical, and machinery sectors are showing strong performance among listed companies [3].